Does newborn screening improve early lung function in cystic fibrosis?

Gwyneth Davies1

  • 1UCL Great Ormond Street Institute of Child Health, London, UK; Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.

Insights

Newborn screening for cystic fibrosis (CF) improves nutrition but its effect on early lung function remains unclear. More research is needed to understand the full impact of CF newborn screening on respiratory health.

Area of Science:

  • Pulmonary Medicine
  • Genetics
  • Pediatrics

Background:

  • Newborn screening (NBS) for cystic fibrosis (CF) has demonstrated benefits in nutritional outcomes.
  • The impact of NBS on early pulmonary outcomes in CF patients is less understood.
  • Evaluating NBS effects on lung function is complicated by evolving clinical practices and public health interventions.

Purpose of the Study:

  • To review methods for measuring early lung function in CF.
  • To summarize knowledge gained from CF NBS cohorts regarding pulmonary outcomes.
  • To compare pulmonary outcomes between infants diagnosed via NBS and those diagnosed symptomatically.

Main Methods:

  • Review of studies on early lung function measurement in CF NBS cohorts.
  • Analysis of comparative studies between NBS and symptomatic diagnosis groups.
  • Assessment of evidence on the impact of NBS on pulmonary outcomes.

Main Results:

  • Evidence for improved nutritional outcomes in CF NBS is established.
  • Data on the impact of NBS on early lung function is currently insufficient for firm conclusions.
  • Spirometry alone may lack sensitivity for detecting early lung disease in CF.

Conclusions:

  • There is insufficient evidence to definitively conclude the effect of NBS on early lung function in CF.
  • Future highly effective CF treatments may allow for earlier intervention, potentially revealing the full impact of NBS on lung function.
  • Further research is required to elucidate the long-term pulmonary benefits of early CF detection through NBS.

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
601
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
333
Pulmonary Function Tests01:25

Pulmonary Function Tests

Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
599